enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
2.520
-0.110 (-4.18%)
Apr 1, 2025, 10:20 AM EDT - Market open

Company Description

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease.

The company’s lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency.

Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh.

The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories.

The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021.

enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

enVVeno Medical Corporation
enVVeno Medical logo
Country United States
Founded 1987
Industry Medical Devices
Sector Healthcare
Employees 37
CEO Robert Berman

Contact Details

Address:
70 Doppler
Irvine, California 92618
United States
Phone 949 261 2900
Website envveno.com

Stock Details

Ticker Symbol NVNO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001661053
CUSIP Number 29415J106
ISIN Number US29415J1060
Employer ID 33-0936180
SIC Code 3841

Key Executives

Name Position
Robert A. Berman Chief Executive Officer and Director
Craig Thomas Glynn Chief Financial Officer, Treasurer and Secretary
Dr. Hamed Alavi Ph.D. Senior Vice President and Chief Technology Officer
Dr. Marc H. Glickman M.D. Senior Vice President and Chief Medical Officer
Warren Hancock Co-founder
Sandy Prietto Vice President of Marketing
Dr. Benedict Broennimann M.D. Chief Medical Officer of Outside of United States
Andrew Cormack Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 14, 2025 EFFECT Notice of Effectiveness
Mar 12, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 12, 2025 S-3/A [Amend] Registration statement under Securities Act of 1933
Feb 28, 2025 S-3 Registration statement under Securities Act of 1933
Feb 28, 2025 10-K/A [Amend] Annual report
Feb 28, 2025 10-K Annual Report
Dec 26, 2024 8-K Current Report
Nov 19, 2024 DEF 14A Other definitive proxy statements
Nov 14, 2024 SCHEDULE 13G/A Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals